Skip to main content

News Releases

 
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
09/30/16FDA Classifies Two Field Actions Related to HeartWare HVAD System as Class 1 RecallsPrinter Friendly Version
08/23/16Medtronic Completes Acquisition of HeartWare InternationalPrinter Friendly Version
07/28/16HeartWare International Reports $68.7 Million In Second Quarter 2016 RevenuePrinter Friendly Version
06/27/16Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare InternationalPrinter Friendly Version
06/01/16HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be WebcastPrinter Friendly Version
05/05/16HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be WebcastPrinter Friendly Version
05/04/16HeartWare International Reports First Quarter 2016 Financial ResultsPrinter Friendly Version
04/27/16HeartWare Completes Enrollment In HVAD® System LATERAL Study™Printer Friendly Version
04/20/16HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual MeetingPrinter Friendly Version
04/19/16HeartWare Schedules First Quarter 2016 Financial Results Conference Call And WebcastPrinter Friendly Version
03/14/16HeartWare Appoints Chadwick M. Cornell To Board Of DirectorsPrinter Friendly Version
03/08/16HeartWare Presentation At The Barclays Global Healthcare Conference To Be WebcastPrinter Friendly Version
03/01/16HeartWare Presentation At The Raymond James 37th Annual Institutional Investors Conference To Be WebcastPrinter Friendly Version
02/25/16HeartWare International Reports Fourth Quarter And Full-Year 2015 Financial ResultsPrinter Friendly Version
02/12/16HeartWare Schedules Fourth Quarter 2015 Financial Results Conference Call And WebcastPrinter Friendly Version
02/03/16HeartWare Presentation At The Leerink Partners 5th Annual Global Healthcare Conference To Be WebcastPrinter Friendly Version
01/28/16HeartWare International Announces Cooperation Agreement With Engaged Capital, LLCPrinter Friendly Version
01/28/16HeartWare International And Valtech Cardio, Ltd. Announce Termination Of Proposed AcquisitionPrinter Friendly Version
01/11/16HeartWare International Provides Corporate Updates And Announces Preliminary Revenue For Fourth Quarter 2015Printer Friendly Version
01/11/16HeartWare Expands Board Of Directors With Appointment Of Stephen N. Oesterle, M.D.Printer Friendly Version
12/30/15HeartWare International Confirms Receipt Of Director Nominations NoticePrinter Friendly Version
12/16/15HeartWare Presentation At The J.P. Morgan Healthcare Conference To Be WebcastPrinter Friendly Version
12/02/15HeartWare Presentation At The Oppenheimer 26th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
11/24/15HeartWare Presentation At The Piper Jaffray 27th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
11/12/15HeartWare Presentation At The Canaccord Genuity 2015 Medical Technology & Diagnostics Forum To Be WebcastPrinter Friendly Version
11/06/15HeartWare Presentation At The Credit Suisse 24th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
11/03/15HeartWare International Announces Expiration Of Hart-Scott-Rodino Waiting Period In Connection With Acquisition Of Valtech CardioPrinter Friendly Version
10/29/15HeartWare International Reports Third Quarter 2015 ResultsPrinter Friendly Version
10/28/15HeartWare International Analyst And Investor Meeting On November 5, 2015 To Be WebcastPrinter Friendly Version
10/20/15HeartWare Schedules Third Quarter 2015 Conference Call And WebcastPrinter Friendly Version
10/05/15HeartWare Issues Statement Regarding Engaged Capital CommentsPrinter Friendly Version
09/03/15HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be WebcastPrinter Friendly Version
09/01/15HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd.Printer Friendly Version
08/10/15HeartWare Completes Enrollment In ENDURANCE2 Supplemental Destination Therapy TrialPrinter Friendly Version
08/04/15HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be WebcastPrinter Friendly Version
07/30/15HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit GrowthPrinter Friendly Version
07/21/15HeartWare Schedules Second Quarter 2015 Conference Call And WebcastPrinter Friendly Version
07/20/15HeartWare International Announces First Human Implants Of The MVAD® System In CE Mark International Clinical TrialPrinter Friendly Version
06/08/15HeartWare International Issues Voluntary Device CorrectionPrinter Friendly Version
06/04/15HeartWare Presentation At The Goldman Sachs 36th Annual Global Healthcare Conference To Be WebcastPrinter Friendly Version
05/07/15HeartWare Announces Private Placement Of $148 Million Of 1.75% Convertible Senior Notes Due 2021Printer Friendly Version
05/04/15HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be WebcastPrinter Friendly Version
04/30/15HeartWare International Reports $70.0 Million In First Quarter 2015 RevenuePrinter Friendly Version
04/22/15HeartWare Schedules First Quarter 2015 Conference Call And WebcastPrinter Friendly Version
04/20/15Contemporary Results From Commercial HVAD® System Registries Highlighted At ISHLT Meeting In Nice, FrancePrinter Friendly Version
04/16/15HeartWare Achieves Primary Endpoint In The ENDURANCE Destination Therapy Clinical TrialPrinter Friendly Version
04/10/15HeartWare Announces Webcasts At The 35th International Society for Heart and Lung Transplantation Annual MeetingPrinter Friendly Version
04/09/15HeartWare International Receives Health Canada Approval For Commercialization Of The HeartWare® Ventricular Assist System As A Bridge To Heart TransplantationPrinter Friendly Version
03/04/15HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be WebcastPrinter Friendly Version
02/26/15HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013Printer Friendly Version
02/25/15HeartWare Presentation At The Raymond James 36th Annual Institutional Investors Conference To Be WebcastPrinter Friendly Version
02/20/15HeartWare International Recalls Certain Older HeartWare® Clinical Trial ControllersPrinter Friendly Version
02/13/15HeartWare Schedules Fourth Quarter Conference Call And WebcastPrinter Friendly Version
02/05/15HeartWare Presentation At The 2015 Leerink Global Healthcare Conference To Be WebcastPrinter Friendly Version
01/13/15HeartWare International Announces Preliminary Fourth Quarter 2014 RevenuesPrinter Friendly Version
01/13/15HeartWare Begins HVAD® LATERAL Study, A Clinical Trial Of Advanced Heart Failure Patients Implanted Via Less-Invasive Thoracotomy TechniquePrinter Friendly Version
01/02/15HeartWare Presentation At The J.P. Morgan 33rd Annual Healthcare Conference To Be WebcastPrinter Friendly Version
12/04/14HeartWare Presentation At The Oppenheimer 25th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
11/13/14HeartWare Presentation At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum To Be WebcastPrinter Friendly Version
11/07/14HeartWare Presentation At The Credit Suisse 2014 Healthcare Conference To Be WebcastPrinter Friendly Version
10/30/14HeartWare International Reports $68.6 Million In Third Quarter 2014 Revenue; 25% Increase From Third Quarter 2013Printer Friendly Version
10/15/14HeartWare Schedules Third Quarter Conference Call And WebcastPrinter Friendly Version
08/05/14HeartWare Presentation At The Canaccord Genuity 34th Annual Growth Conference To Be WebcastPrinter Friendly Version
08/04/14HeartWare International Announces Appointment Of Katrin Leadley, M.D., As Chief Medical OfficerPrinter Friendly Version
07/31/14HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013Printer Friendly Version
07/17/14HeartWare Schedules Second Quarter Conference Call And WebcastPrinter Friendly Version
06/12/14HeartWare Presentation at the 2014 Wells Fargo Healthcare Conference to Be WebcastPrinter Friendly Version
06/06/14HeartWare Presentation At The Goldman Sachs 35th Annual Global Healthcare Conference To Be WebcastPrinter Friendly Version
06/04/14HeartWare International Comments On FDA Warning LetterPrinter Friendly Version
06/03/14HeartWare Presentation At The William Blair & Company 34th Annual Growth Stock Conference To Be WebcastPrinter Friendly Version
05/09/14HeartWare Presentation At The Bank Of America Merrill Lynch 2014 Health Care Conference To Be WebcastPrinter Friendly Version
05/01/14HeartWare International Reports $66.5 Million In First Quarter 2014 Revenue; 35% Increase From First Quarter 2013Printer Friendly Version
05/01/14HeartWare International Issues Voluntary Device Correction For HeartWare® BatteriesPrinter Friendly Version
04/24/14HeartWare Issues Reminder To December 2013 Driveline Connector Device CorrectionPrinter Friendly Version
04/22/14HeartWare Schedules First Quarter Conference Call And WebcastPrinter Friendly Version
03/07/14HeartWare Presentation At The 2014 Barclays Global Healthcare Conference To Be WebcastPrinter Friendly Version
02/27/14HeartWare International Reports Fourth Quarter 2013 ResultsPrinter Friendly Version
02/26/14HeartWare Presentation At The Raymond James 35th Annual Institutional Investors Conference To Be WebcastPrinter Friendly Version
02/04/14HeartWare Schedules Fourth Quarter Conference Call And WebcastPrinter Friendly Version
02/04/14HeartWare Presentation At The 2014 Leerink Global Healthcare Conference To Be WebcastPrinter Friendly Version
01/14/14HeartWare International Announces Preliminary Fourth Quarter 2013 RevenuesPrinter Friendly Version
12/20/13HeartWare Presentation At The 32nd Annual J.P. Morgan Healthcare Conference To Be WebcastPrinter Friendly Version
12/06/13HeartWare Presentation At The Oppenheimer 24th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
12/01/13HeartWare® International Announces Acquisition Of CircuLite®, Inc.Printer Friendly Version
11/25/13HeartWare Presentation At The 25th Annual Piper Jaffray Healthcare Conference To Be WebcastPrinter Friendly Version
11/08/13HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be WebcastPrinter Friendly Version
11/07/13HeartWare International Reports $54.8 Million In Third Quarter 2013 Revenue; 140% Increase From Third Quarter Of 2012Printer Friendly Version
11/05/13HeartWare Presentation At The Credit Suisse Healthcare Conference To Be WebcastPrinter Friendly Version
10/25/13HeartWare Schedules Third Quarter Conference Call And WebcastPrinter Friendly Version
08/27/13HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy TrialPrinter Friendly Version
08/09/13HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be WebcastPrinter Friendly Version
08/08/13HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue; 75% Increase From Second Quarter Of 2012Printer Friendly Version
07/19/13HeartWare Schedules Second Quarter Conference Call And WebcastPrinter Friendly Version
06/17/13HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy TrialPrinter Friendly Version
06/13/13HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be WebcastPrinter Friendly Version
06/04/13HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be WebcastPrinter Friendly Version
05/16/13HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be WebcastPrinter Friendly Version
05/10/13HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be WebcastPrinter Friendly Version
04/29/13HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012Printer Friendly Version
04/15/13HeartWare Schedules First Quarter Conference Call And WebcastPrinter Friendly Version
03/18/13HeartWare International, Inc. Announces Closing of Public Offering of Common StockPrinter Friendly Version
03/12/13HeartWare International, Inc. Announces Pricing of Public Offering of Common StockPrinter Friendly Version
03/11/13HeartWare International, Inc. Announces Public Offering of Common StockPrinter Friendly Version
03/06/13HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be WebcastPrinter Friendly Version
02/28/13HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be WebcastPrinter Friendly Version
02/27/13HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 MillionPrinter Friendly Version
02/19/13HeartWare Schedules Fourth Quarter Conference Call and WebcastPrinter Friendly Version
02/08/13HeartWare Presentation at Leerink Swann Global Healthcare Conference to be WebcastPrinter Friendly Version
01/07/13HeartWare International Announces Preliminary Fourth Quarter 2012 RevenuesPrinter Friendly Version
01/03/13HeartWare Presentation At The 31st Annual J.P. Morgan Healthcare Conference To Be WebcastPrinter Friendly Version
12/06/12HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be WebcastPrinter Friendly Version
11/20/12HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart FailurePrinter Friendly Version
11/16/12HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be WebcastPrinter Friendly Version
11/09/12HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
11/09/12HeartWare Reports Third Quarter 2012 ResultsPrinter Friendly Version
11/01/12HeartWare Schedules Third Quarter Conference Call And WebcastPrinter Friendly Version
09/14/12HeartWare Presentation at the UBS Global Life Sciences Conference to be WebcastPrinter Friendly Version
08/10/12HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be WebcastPrinter Friendly Version
08/09/12HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be WebcastPrinter Friendly Version
08/07/12HeartWare Reports Second Quarter 2012 ResultsPrinter Friendly Version
08/02/12HeartWare Completes Acquisition Of World Heart CorporationPrinter Friendly Version
07/30/12HeartWare Schedules Second Quarter Conference Call And WebcastPrinter Friendly Version
07/09/12HeartWare Names Peter F. McAree Chief Financial OfficerPrinter Friendly Version
05/23/12HeartWare Announces Publication Of Results From U.S. Bridge-To-Transplant Clinical TrialPrinter Friendly Version
05/23/12HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart FailurePrinter Friendly Version
05/10/12HeartWare International Reports First Quarter 2012 Revenue of $26.3 Million; 47% Increase From $18.0 Million in First Quarter 2011Printer Friendly Version
05/08/12HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical TrialPrinter Friendly Version
05/07/12HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be WebcastPrinter Friendly Version
05/03/12Heartware Schedules First Quarter Conference Call And WebcastPrinter Friendly Version
04/25/12FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System as Bridge to Transplant for Patients With End-Stage Heart FailurePrinter Friendly Version
04/25/12HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart TransplantationPrinter Friendly Version
03/29/12HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 MillionPrinter Friendly Version
03/16/12HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
03/06/12HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be WebcastPrinter Friendly Version
02/16/12HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million; Full Year 2011 Revenues of $82.8 Million; 50% Increase From $55.2 Million in 2010Printer Friendly Version
02/14/12HeartWare Announces Date for FDA Advisory Committee PanelPrinter Friendly Version
02/06/12HeartWare Schedules Fourth Quarter Conference Call and WebcastPrinter Friendly Version
01/09/12HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist SystemPrinter Friendly Version
01/04/12HeartWare to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
12/09/11HeartWare to Present at the Oppenheimer 22nd Annual Healthcare ConferencePrinter Friendly Version
11/23/11HeartWare to Present at the 23rd Annual Piper Jaffray Health Care ConferencePrinter Friendly Version
11/10/11HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare ConferencePrinter Friendly Version
11/04/11HeartWare to Present at the Credit Suisse 2011 Healthcare ConferencePrinter Friendly Version
10/27/11HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010Printer Friendly Version
10/27/11HeartWare International Announces Planned Departure of Chief Financial OfficerPrinter Friendly Version
10/21/11HeartWare Schedules Third Quarter Conference Call and WebcastPrinter Friendly Version
10/02/11HeartWare Reports Additional Clinical Data From Bridge-to-Transplant and Continued Access Patients at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Meeting in LisbonPrinter Friendly Version
09/28/11HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in LisbonPrinter Friendly Version
09/19/11HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device DayPrinter Friendly Version
09/14/11HeartWare to Present at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/09/11HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP CongressPrinter Friendly Version
08/12/11HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access ConferencePrinter Friendly Version
08/08/11HeartWare to Present at the Canaccord Genuity 31st Annual Growth ConferencePrinter Friendly Version
08/04/11HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010Printer Friendly Version
07/27/11HeartWare to Report Financial Results for Second Quarter of 2011Printer Friendly Version
06/16/11HeartWare to Present at the Wells Fargo 2011 Healthcare ConferencePrinter Friendly Version
05/06/11HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care ConferencePrinter Friendly Version
05/05/11HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010Printer Friendly Version
04/28/11HeartWare Supplemental Addendum to CE Mark Accepted by BSIPrinter Friendly Version
04/26/11HeartWare to Report 2011 First Quarter Financial ResultsPrinter Friendly Version
04/15/11HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access PatientsPrinter Friendly Version
04/12/11HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual MeetingPrinter Friendly Version
03/24/11HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in AustraliaPrinter Friendly Version
03/07/11HeartWare to Present at the Barclays Capital 2011 Global Healthcare ConferencePrinter Friendly Version
02/24/11HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009Printer Friendly Version
02/15/11HeartWare to Report 2010 Fourth Quarter and Year-End Financial ResultsPrinter Friendly Version
01/24/11HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
01/04/11HeartWare to Present at the 29th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
12/28/10HeartWare Files PMA Application for FDA Approval of the HeartWare(R) Ventricular Assist System for a Bridge-to-Transplant IndicationPrinter Friendly Version
12/15/10HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common StockPrinter Friendly Version
12/10/10HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common StockPrinter Friendly Version
12/09/10HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common StockPrinter Friendly Version
12/02/10HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity ConferencePrinter Friendly Version
11/18/10HeartWare to Present at the 22nd Annual Piper Jaffray Health Care ConferencePrinter Friendly Version
11/14/10HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCEPrinter Friendly Version
11/11/10HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare ConferencePrinter Friendly Version
11/09/10HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010Printer Friendly Version
11/03/10HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009Printer Friendly Version
10/20/10HeartWare to Report Financial Results for Third Quarter of 2010Printer Friendly Version
09/23/10Appendix 3BPrinter Friendly Version
09/23/10HeartWare to Present at Lazard Capital Markets Circulatory Assist Device DayPrinter Friendly Version
09/15/10HeartWare to Present at the UBS 2010 Global Life Sciences ConferencePrinter Friendly Version
09/03/10HeartWare Receives Second Patient Allotment Under Continued Access Protocol for Pivotal U.S. Bridge-To-Transplant Clinical TrialPrinter Friendly Version
08/05/10HeartWare International Reports Second Quarter 2010 Revenues of $9.8 Million; Compared to $3.0 Million in Second Quarter 2009Printer Friendly Version
08/04/10HeartWare to Present at The Canaccord Genuity 30th Annual Growth ConferencePrinter Friendly Version
07/29/10HeartWare to Present at the Wedbush Securities 2010 Life Sciences Best Ideas ConferencePrinter Friendly Version
07/27/10HeartWare to Report Financial Results for Second Quarter of 2010Printer Friendly Version
06/24/10HeartWare Announces Board SuccessionPrinter Friendly Version
06/17/10HeartWare to Present at the Wells Fargo Securities 2010 Healthcare ConferencePrinter Friendly Version
06/14/10HeartWare Receives Conditional FDA Approval to Commence Pivotal Destination Therapy Clinical Trial in the U.S.Printer Friendly Version
05/06/10HeartWare to Present at Bank of America Merrill Lynch Health Care Conference in New YorkPrinter Friendly Version
05/03/10HeartWare International Reports First Quarter 2010 Revenues of $10.7 Million; Compared With $1.5 Million In First Quarter 2009Printer Friendly Version
04/26/10HeartWare Initiates Repairs and Partial Recall of ControllersPrinter Friendly Version
04/23/10HeartWare Data From First 100 Patients in International Clinical and Commercial Experience Shows 90% Survival at 180 DaysPrinter Friendly Version
04/12/10HeartWare to Report Financial Results for First Quarter of 2010Printer Friendly Version
04/07/10HeartWare Receives FDA Approval of Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
03/11/10HeartWare to Present at the Barclays Capital 2010 Global Healthcare ConferencePrinter Friendly Version
03/04/10HeartWare to Present at the Roth Capital Partners OC Growth Stock ConferencePrinter Friendly Version
02/22/10HeartWare International Reports Fourth Quarter Revenues of $12.2 Million; Full Year 2009 Revenues of $24.2 MillionPrinter Friendly Version
02/22/10HeartWare Announces Early Conclusion of Enrollment for U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
02/08/10HeartWare to Report 2009 Fourth Quarter and Year-End Financial ResultsPrinter Friendly Version
02/02/10HeartWare International, Inc. Announces Completion of Public Offering of Common StockPrinter Friendly Version
01/27/10HeartWare International, Inc. Announces Pricing of Public Offering of Common StockPrinter Friendly Version
01/26/10HeartWare International, Inc. Announces Commencement of Public Offering of Common StockPrinter Friendly Version
01/06/10HeartWare to Present at J.P. Morgan Healthcare Conference in San FranciscoPrinter Friendly Version
11/25/09HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York CityPrinter Friendly Version
11/04/09HeartWare International Reports Third Quarter Revenues of $7.5 MillionPrinter Friendly Version
10/05/09U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
09/01/09HeartWare International, Inc. Temporary Suspension of TradingPrinter Friendly Version
08/20/09HeartWare International Surpasses 50 Implants in the USPrinter Friendly Version
08/17/09HeartWare International, Inc. Closes US$60 Million FinancingPrinter Friendly Version
08/11/09HeartWare to Present at Canaccord Adams 29th Annual Global Growth ConferencePrinter Friendly Version
08/10/09HeartWare International, Inc. Announces US$55 Million FinancingPrinter Friendly Version
07/31/09Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed TransactionPrinter Friendly Version
07/29/09U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare InternationalPrinter Friendly Version
05/12/09HeartWare to Present at Eighth Annual JMP Securities Research ConferencePrinter Friendly Version
04/24/09HeartWare International Clinical Trial Shows 90% Survival at 180 DaysPrinter Friendly Version